-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Drop in Short Interest
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Drop in Short Interest
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 154,900 shares, a decrease of 18.6% from the October 15th total of 190,300 shares. Based on an average daily volume of 75,200 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.5% of the company's shares are sold short.
Bluejay Diagnostics Stock Performance
Bluejay Diagnostics stock traded up $0.03 during trading on Tuesday, hitting $0.73. The company's stock had a trading volume of 52,876 shares, compared to its average volume of 54,507. The stock's fifty day moving average is $0.84 and its 200 day moving average is $1.03. Bluejay Diagnostics has a 1-year low of $0.61 and a 1-year high of $4.47.
Get Bluejay Diagnostics alerts:Institutional Investors Weigh In On Bluejay Diagnostics
A number of large investors have recently modified their holdings of BJDX. Millennium Management LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $27,000. Virtu Financial LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $45,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $54,000. Institutional investors and hedge funds own 1.21% of the company's stock.
Bluejay Diagnostics Company Profile
(Get Rating)Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
Featured Articles
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 154,900 shares, a decrease of 18.6% from the October 15th total of 190,300 shares. Based on an average daily volume of 75,200 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.5% of the company's shares are sold short.
BlueJay诊断公司(纳斯达克代码:BJDX-GET Rating)是空头股数10月份销量大幅下降的接收方。截至10月31日,空头股数共有154,900股,较10月15日的190,300股减少18.6%。以日均成交量75,200股计算,目前天数与回补比率为2.1天。目前,该公司1.5%的股票被卖空。
Bluejay Diagnostics Stock Performance
BlueJay诊断公司股票表现
Bluejay Diagnostics stock traded up $0.03 during trading on Tuesday, hitting $0.73. The company's stock had a trading volume of 52,876 shares, compared to its average volume of 54,507. The stock's fifty day moving average is $0.84 and its 200 day moving average is $1.03. Bluejay Diagnostics has a 1-year low of $0.61 and a 1-year high of $4.47.
BlueJay诊断公司的股票在周二的交易中上涨了0.03美元,达到0.73美元。该公司股票的成交量为52,876股,而其平均成交量为54,507股。该股的50日移动均线切入位为0.84美元,200日移动均线切入位为1.03美元。BlueJay Diagnostics的一年低点为0.61美元,一年高位为4.47美元。
Institutional Investors Weigh In On Bluejay Diagnostics
机构投资者参与Bluejay Diagnostics
A number of large investors have recently modified their holdings of BJDX. Millennium Management LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $27,000. Virtu Financial LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $45,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $54,000. Institutional investors and hedge funds own 1.21% of the company's stock.
一些大型投资者最近调整了对BJDX的持股。Millennium Management LLC在第二季度收购了Bluejay Diagnostics的新股份,价值约2.7万美元。Virtu Financial LLC在第二季度收购了Bluejay Diagnostics的新股份,价值约4.5万美元。最后,复兴科技有限责任公司在第二季度收购了Bluejay Diagnostics的新股份,价值约5.4万美元。机构投资者和对冲基金持有该公司1.21%的股票。
Bluejay Diagnostics Company Profile
BlueJay诊断公司简介
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
BlueJay诊断公司是一家诊断公司,在美国开发和销售用于分诊、诊断和监测疾病进展的患者产品。它正在开发一个技术平台,包括使用非接触式离心力协调血液处理、生物标记物分离和免疫分析准备的SYMPHONY荧光免疫分析仪;以及包括试剂和组件的SYMPHONY卡片库。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
- 免费获取StockNews.com关于Bluejay诊断的研究报告(BJDX)
- 不要追逐沃尔玛更高,等待超低价格
- 家得宝的业绩(和机构)是劳氏的催化剂吗?
- 三只细价股在11月大动干戈
- 安捷伦在下周第四季度报告发布前仍在买入区间
- WayFair仍有其公平份额的问题
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Bluejay诊断日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Bluejay Diagnostics和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧